Article
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2015
Carlino Matteo S, Fung Carina, Shahheydari Hamideh, Todd Jason R, Boyd Suzanah C, Irvine Mal, Nagrial Adnan M, Scolyer Richard A, Kefford Richard F, Long Georgina V, Rizos Helen
Abstract excerpt
BACKGROUND: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors, although preexisting MEK1(P124) mutations do not preclude clinical responses. We sought to determine whether recurrent, preexisting MEK1(P124) mutations affected clinical outcome in BRAF inhibitor-treated patients with melanoma. METHODS: Data from four published datasets were analyzed to determine whether preexisting MEK1(P124)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.